Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2002
12/12/2002WO2002090313A8 Aloe-emodin derivatives and their use in the treatment of neoplastic pathologies
12/12/2002WO2002087600A8 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
12/12/2002WO2002082044A3 Method of imaging cell death in vivo
12/12/2002WO2002080890A3 A jasmonate pharmaceutical composition for treatment of cancer
12/12/2002WO2002076977A3 Rho-kinase inhibitors
12/12/2002WO2002076976A3 Rho-kinase inhibitors
12/12/2002WO2002074798A3 The genome of a bifidobacterium
12/12/2002WO2002074756A3 Urokinase inhibitors
12/12/2002WO2002074327A3 Compositions and methods for treating gonadotrophin related illnesses
12/12/2002WO2002072015A3 M cell directed vaccines
12/12/2002WO2002068015A9 Modular infusion device and method
12/12/2002WO2002066458A3 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
12/12/2002WO2002066415A3 Non-steroidal modulators of estrogen receptors
12/12/2002WO2002064591A3 Carboline derivatives
12/12/2002WO2002064552A8 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
12/12/2002WO2002064080A3 Matrix metalloproteinase inhibitors
12/12/2002WO2002062972A3 Hybridoma cell line g250 and its use for producing monoclonal antibodies
12/12/2002WO2002062792A9 Jnk inhibitor
12/12/2002WO2002061052A3 An improved in vitro method of culturing mammalian cells for autologous cell implantation/transplantation methods
12/12/2002WO2002046232A3 Multimeric single-chain antibody with multiple antigen binding
12/12/2002WO2002033090A3 Pharmaceutical preparations and methods for inhibiting tumors
12/12/2002WO2002018593A3 Modulation of fas and fasl expression
12/12/2002WO2002018557A3 Human kinases
12/12/2002WO2002002077A3 Liposomal antineoplastic drugs and uses thereof
12/12/2002WO2001097850A3 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/12/2002WO2001093983A9 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/12/2002WO2001089568A9 Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
12/12/2002WO2001078720A8 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
12/12/2002WO2001054731A3 Ligand conjugates and methods for preparing same
12/12/2002WO2001018207A9 Human 7tm proteins receptors and polynucleotides encoding the same
12/12/2002US20020188142 17-Side chain alkynyl-and 20-oxopregna-derivatives of vitamin D, methods for their production and pharmaceutical compositions thereof
12/12/2002US20020188122 Such as pyridine-4-carboxaldehyde-(4-Morpholinylprop-3-yl) imine for use in therapy as cytokine inhibitors
12/12/2002US20020188107 Plant protein for use in the treatment of cancer
12/12/2002US20020188100 Boron compound for use in the treatment of stroke, heart defects, inflammation, autoimmune and cancer disease
12/12/2002US20020188018 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
12/12/2002US20020188014 Polymorphs of an epothilone analog
12/12/2002US20020187993 Bifunctional energy-reversible acyl-compositions
12/12/2002US20020187992 Prodrugs via acylation with cinnamate
12/12/2002US20020187991 Barbituric acid derivatives
12/12/2002US20020187978 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
12/12/2002US20020187976 New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
12/12/2002US20020187973 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187970 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
12/12/2002US20020187969 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187968 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
12/12/2002US20020187967 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187966 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187965 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187964 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187963 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187962 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
12/12/2002US20020187956 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
12/12/2002US20020187954 Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to modulate cell growth
12/12/2002US20020187938 Ghrelin antagonists
12/12/2002US20020187534 Treating cancer by increasing intracellular malonyl CoA levels
12/12/2002US20020187523 Extracellular signaling molecules
12/12/2002US20020187492 Nucleotide sequences coding polypeptides for use in the treatnment of inflammation
12/12/2002US20020187473 Polyamide nucleic acid derivatives, and agents and processes for preparing them
12/12/2002US20020187472 Nucleotide sequences coding protein for use in the treatment of cancer
12/12/2002US20020187191 Oxidized collagen formulations for use with non-compatible pharmaceutical agents
12/12/2002US20020187163 Herpes simplex virus comprising a mutation within the BstEII-EcoNI fragment of the BamHI x fragment of said virus; cancer vaccine
12/12/2002US20020187145 Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
12/12/2002US20020187144 Useful for treating patients with colorectal cancer and gastric carcinomas; particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
12/12/2002US20020187141 Composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent; determination whether the failure of traditional chemotherapy is due to multidrug resistant tumor cells
12/12/2002US20020187140 Two novel human cathepsin proteins
12/12/2002US20020187125 Reovirus for the treatment of neoplasia
12/12/2002US20020187105 Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
12/12/2002CA2830887A1 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
12/12/2002CA2457959A1 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
12/12/2002CA2450009A1 Method and apparatus for treating tumors using low strength electric fields
12/12/2002CA2449940A1 Bcl-2 dnazymes
12/12/2002CA2449877A1 Tetramerous derivative of indole-3-carbinol with anti-carcinogenic activity and method of synthesis of said derivative
12/12/2002CA2449843A1 Non-peptide gnrh agents, pharmaceutical compositions and methods for their use, and processes for preparing them
12/12/2002CA2449771A1 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
12/12/2002CA2449770A1 Novel anti-infectives
12/12/2002CA2449670A1 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002CA2449663A1 Mutant forms of cholera holotoxin as an adjuvant
12/12/2002CA2449658A1 Use of rank antagonists to treat cancer
12/12/2002CA2449487A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
12/12/2002CA2449482A1 Chds as modifiers of the p53 pathway and methods of use
12/12/2002CA2449479A1 Map3ks as modifiers of the p53 pathway and methods of use
12/12/2002CA2449450A1 Cancer treatment method and compositions comprising compounds of the ginger family
12/12/2002CA2449425A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002CA2449316A1 Novel metalloporphyrins and their uses as radiosensitizers for radiation therapy
12/12/2002CA2449289A1 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002CA2449281A1 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002CA2449275A1 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002CA2449270A1 Pibs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449267A1 Hs2sts as modifiers of the p53 pathway and methods of use
12/12/2002CA2449221A1 P5crs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449206A1 Cads as modifiers of the p53 pathway and methods of use
12/12/2002CA2449175A1 Use of methylnaltrexone to treat immune suppression
12/12/2002CA2449136A1 Igs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449135A1 Adsls as modifiers of the p53 pathway and methods of use
12/12/2002CA2449109A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002CA2449097A1 5-ethyl-imidazotriazinones
12/12/2002CA2449077A1 Epothilone derivatives
12/12/2002CA2449021A1 Novel compounds and compositions as cathepsin inhibitors
12/12/2002CA2448828A1 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2
12/12/2002CA2448606A1 Nucleic acid-associated proteins
1 ... 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 ... 2211